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Abstract
Wiskott-Aldrich syndrome (WAS) is a clinical condition characterized by thrombocytopenia, eczema, 
and life-threatening infections. In some cases autoimmunity-related problems and even malignancy 
might be seen; however, some patients have milder clinical manifestations due to mutations in the 
same gene family, such as in X-linked thrombocytopenia (XLT), which is generally not associated with 
serious symptoms of disease, except for thrombocytopenia. Herein we report 2 siblings with chronic 
thrombocytopenia that were diagnosed with XLT based on a missense mutation in the WASP gene 
(223G>A, Val75Met). To the best of our knowledge this mutation has not been previously reported in 
a Turkish patient with XLT. (Turk J Hematol 2011; 28: 139-41)
Key words: X-linked thrombocytopenia, Wiskott-Aldrich syndrome, WASP gene
Received: January 25, 2011     Accepted: April 11, 2011 
Özet
Wiskott Aldrich Sendromu (WAS) trombositopeni, egzema ve hayatı tehdit edici enfeksiyonlar ile 
karakterize klinik durumdur. Bazı vakalarda otoimmünite ile ilgili problemler hatta malign hastalıklar 
da görülebilmektedir. Bunların yanında aynı gen ailesinden köken alan bazı mutasyonlarda daha hafif 
klinik seyir görülmektedir. X’e bağlı trombositopeni bunlardan biri olup genellikle trombositopeni 
dışındaki ciddi semptomları taşımaz. Burada kronik trombositopenisi olan iki erkek kardeş, WASP 
geninde bir missens mutasyona bağlı X’e bağlı trombositopeni tanısı almaları nedeniyle sunulmuştur. 
Bu mutasyon bildiğimiz kadarıyla X’e bağlı trombositopeni tanılı Türk hastalarda daha önce bildiril-
memiştir. (Turk J Hematol 2011; 28: 139-41)
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X-linked thrombocytopenia (XLT) is a congenital 
disease characterized by small platelets and a clini-
cal spectrum that generally does not include other 
features of Wiskott-Aldrich syndrome (WAS), such 
as eczema and recurrent infections. XLT belongs to 
a disorder group related with the WAS gene family,   
which is expressed selectively in the hematopoietic 
stem cell-derived lineage that encodes WAS protein 
(WASP) functioning in cellular motility, the cytoskel-
eton, signaling, and apoptosis. According to the lit-
erature,  the  condition  is  common  in  Europe  and 
Japan [1]; however, XLT with the detected muta-
tional analysis is not common in Turkey. Herein we 
present  2  brothers  with  XLT  mutation  (223G>A, 
Val75Met), which to the best of our knowledge has 
not been previously described in a Turkish family. 
Case Reports
Patient 1
Patient  1  was  a  7-year-old  boy  that  has  had 
ecchymosis and mucosal bleeding since the age of 
2 years. Laboratory investigation showed moderate 
thrombocytopenia  (platelet  count:  20.000-50.000 
mm-3) and peripheral blood smear showed throm-
bocytopenia  and  small  platelets  (MPV:  5  fL).  The 
patient’s history of eczema, and recurrent or life-
threatening  infection,  which  are  observed  in  the 
classical WAS clinical picture, was negative. Other 
findings associated with WAS, including lymphope-
nia,  staphylococcal  superinfections,  and  opportu-
nistic infections, were not observed during follow-
up.  The  patient  was  previously  followed-up  at 
another clinic as chronic idiopathic thrombocytope-
nic purpura, and received such treatments as intra-
venous immunoglobulin therapy until last 2 years. 
Upon  presentation  to  our  hematology  clinic  at 
Gaziantep  Children’s  Hospital,  physical  examina-
tion findings were normal, except for generalized 
petechial lesions. As XLT was considered, he was 
treated  with  thrombocyte  suspensions  when  pro-
longed mucosal bleeding occurred and when the 
hemoglobin  level  dropped.  No  treatments  were 
administered  to  alter  the  patient’s  platelet  count. 
The patient had multiple head traumas that resulted 
in scalp hematomas, but no intracranial bleeding. 
Patient 2
Patient 2 was the 5-year-old bother of patient 1 
and had identical symptoms since the age of 1 year, 
with  severe  thrombocytopenia  (platelet  count: 
≅10,000 mm-3). Patient did not have other findings 
associated with WAS, such as eczema, and recur-
rent or life-threatening infections. He received the 
same  treatment  as  his  brother  (patient  1).  Their 
father and mother are first cousins. 
After  the  patient’s  were  followed-up  by  the 
hematology department because of the familial pat-
tern and microthrombocytes, XLT was suspected. 
After written informed consent was obtained from 
the patients’ parents, mutational analysis was per-
formed  by  Kazusa  DNA  Research  Institute  and 
National Defense Medical Collage in Japan, accord-
ing to their published method (2). A missense muta-
tion  [WAS:  Exon  2,  G→A,  V→M  (c.223G>A, 
Val75Met)]  was  observed  at  exon  2  after  purified 
genomic DNA samples were amplified with primer 
pairs designed to span each exon and exon/intron 
junction; the specific causative mutation was identi-
fied via direct sequencing. At the time this report 
was written the 2 patients were being monitored 
closely  for  bleeding  and  symptoms  of  infection. 
They did not require antibiotic prophylaxis or stem 
cell transplantation, but splenectomy was consid-
ered as a treatment to improve their bleeding status 
by increasing platelet count.
Discussion
WAS gene-related conditions are divided into 3 
clinical groups: WAS, XLT, and X-linked neutropenia 
[3,4]. Whereas mutations that distort WASP expres-
sion and result in the classical WAS clinical symp-
toms, including eczema and life-threatening infec-
tions, in addition to microthrombocytopenia, muta-
tions that result in defective WASP production, such 
as missense mutations, cause the milder phenotype 
XLT, which has a better prognosis; however, muta-
tion,  WASP  production,  and  the  genotype-pheno-
type relationship show individual differences.
The  WASP  gene  encodes  WASP ,  a  502  amino 
acid protein that plays a critical role actin cytoskel-
eton organization, signaling, and immune cell func-
tion [5]. This protein has multiple functional domains 
used in actin polymerization, cellular motility, intra-
cellular signaling, and apoptosis [6]. The actin cyto-
Leblebisatan et al.
Familial thrombocytopenia in a Turkish family Turk J Hematol 2011; 28: 139-41 140skeleton is active in the basic mechanisms of cell 
adhesion and migration. Major dynamic rearrange-
ment of the actin cytoskeleton facilitates cell protru-
sion,  retraction,  adhesion,  and  detachment  for 
migration through tissues and endothelial barriers 
via WASP participation in the transduction of signals 
from the cell surface to the actin cytoskeleton (7).
A recent study on XLT mutations that included 
178 patients from 11 European countries and Japan 
identified 62 unique mutations located primarily on 
exon 1 and exon 2-the majority of which were mis-
sense mutations. One of the 3 most common muta-
tions  is  valine  at  position  75  (Val75Met),  as  was 
observed in the presented patients. This mutation 
was observed in 22 patients from 16 families in 7 
countries  [1].  A  study  that  included  262  patients 
from 227 families (including Turkish cases) reported 
nonsense mutations 950 G>T at exon 9 and 1124 
C>T at exon 10, missense mutations 138 T>A at 
exon 1, 290 C>T at exon 2, 1115C>A at exon 10, and 
1542G>C at exon 12, as well as 1 splice mutation at 
exon 10 in the WASP gene of Turkish patients other 
than  the  mutation  in  the  presented  cases  [8].  A 
novel  mutation  at  exon  4  was  also  reported  in  a 
Turkish  patient  [9].  The  presented  cases  did  not 
have a novel mutation, but to the best of our knowl-
edge this is the first report of XLT mutation (223G>A, 
Val75Met) in a Turkish family.
Patients  with  classical  WAS  require  stem  cell 
transplantation, whereas those with milder variants 
(XLT) may not. Overall survival among German XLT 
patients was reported to be excellent, though some 
exhibited features of WAS, including mild eczema 
and  infections.  Because  the  genotype-phenotype 
relationship is not unique, in terms of mutations and 
WASP production, treatment must be evaluated on 
an individual basis. Proper treatment is based on 
clinical suspicion, followed by a correct diagnosis. 
Treatment options include splenectomy to increase 
the platelet count; however, it is associated with a 
high infection rate and cases without an increase in 
thrombocytes  following  splenectomy  have  been 
reported. Splenectomized patients require life-long 
antibiotic  prophylaxis.  Stem  cell  transplantation 
must be considered on a patient-by-patient basis, as 
some XLT patients have excellent survival, where 
others have significant morbidity and mortality sec-
ondary to life threatening bleedings [1]. 
We presented 2 brothers with XLT and a previ-
ously unreported mutation from Turkey in order to 
emphasize that in patients with chronic thrombocy-
topenia associated with a low platelet count genetic 
analysis  of  WAS  is  necessary  for  the  differential 
diagnosis of diseases of chronic thrombocytopenia 
and  for  preventing  administration  of  unnecessary 
treatments. 
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